Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share
Insulet stock jumps on strong Q3 results, beating estimates with $842M in revenue, raising its 2026 outlook, and launching a $1B buyback.
Share
Why It Matters
Insulet had a great quarter and is buying back its own stock. But the CEO said growth will slow down next year as other companies compete.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.